#### **Company Overview** Jagsonpal Pharmaceuticals Limited (JPL), established in **1978** and headquartered in **Delhi, India**, is a leading mid-sized specialty pharmaceutical company with over **four decades of presence** in the Indian healthcare market. Listed on the **National Stock Exchange (NSE: JAGSNPHARM)** and **Bombay Stock Exchange (BSE: 507789)**, the company is known for its **strong brand equity, physician trust, and disciplined execution**. In **May 2024**, **Infinity Holdings** acquired a majority stake, becoming a **joint promoter**, marking a strategic shift toward professionalization and accelerated growth. --- #### **Core Business & Therapeutic Focus** Jagsonpal specializes in **branded generics and specialty formulations** across four key therapeutic segments: 1. **Gynaecology** (core strength, ~50% of revenue) 2. **Orthopaedics** (~20%) 3. **Dermatology** 4. **Paediatrics/Child Care** The company focuses on **sub-chronic, niche therapy areas** that are **less vulnerable to generic competition and pricing pressure**, enabling **sustainable margins and leadership positioning**. It has **20+ brands ranked among the top 5** in their respective molecule categories, with **5 brands ranked #1**. **Market Leadership:** - **Progesterone Therapeutic Segment (Dydrogesterone)**: Strong hold via brands *Divatrone* and *ProRetro*. - **Top 10** player in the Indian **gynaecology** segment. - **#13** in its addressed therapeutic markets; improved to **#73 overall** in Indian pharma rankings post-acquisition (from #91). --- #### **Business Model: Asset-Light & Scalable** Jagsonpal operates an **efficient, scalable, asset-light model**, outsourcing: - **R&D**: Partnered with leading **Contract Development and Manufacturing Organizations (CDMOs)**. - **Manufacturing**: Sourced from **top-tier Indian CMOs** compliant with **WHO-GMP and ISO 9001:2015**, with **300+ quality checks** per product batch. The company owns **no manufacturing facilities**, having **divested its Faridabad unit in FY24 for ₹410 million**, improving capital efficiency and strategic flexibility. --- #### **Growth Strategy (Three-Pillar Approach)** 1. **Innovation-Driven New Product Launches** - Targets **4–6 niche, differentiated products annually**, including **first-time-in-India formulations** (e.g. *MemUp, Queezy-ER*). - Launches 1–2 new products per quarter via **in-house ideation**, emphasizing **scientific differentiation and concept selling**. - Avoids crowded markets (e.g., GLP-1 inhibitors at patent expiry) to ensure **sustainable growth**. 2. **Volume Growth through Sales Force Optimization** - Employs **over 1,000 medical representatives** (up from ~900 in 2024), trained via structured programs: - **STEP (Scientific Training & Empowerment Program)** - **VLEAD & PROGM** leadership programs to reduce attrition and enhance productivity. - Engages **150,000+ doctors** nationwide, covering approximately **90% of India’s gynaecologists (35,000/39,000)**. 3. **Selective Price Optimization** - Implements **price increases (up to 10% regulatory limit)** primarily in **non-NLEM (non-essential medicines)** portfolio. - Maintains competitive pricing for market stability and brand loyalty. --- #### **Key Acquisitions & Inorganic Growth** **1. Acquisition of Yash Pharma (India & Bhutan) – May 2024** - **Deal Value**: ₹92.47 crore (funded via internal accruals). - **Added**: 33 established brands (4 in **top 10** of their segments). - **Strategic Impact**: - Expanded into **dermatology & paediatrics**, high-growth ₹20,000 crore+ markets. - Strengthened presence in **Western and Eastern India** (Kerala, Maharashtra, Karnataka). - Increased **prescriber base by 50%** (from 100,000 to 150,000). - Grew field force by **~225 medical reps**; total now exceeds **1,000**. - Improved **national ranking by 18 positions** (to #73 in IQVIA). - Addressable market expanded from **₹100 billion to ₹250 billion**. **2. Acquisition of Resilient Cosmeceuticals (India & Bhutan) – Feb 2025** - **Deal Value**: ₹24 crore (internal funding). - **Key Additions**: - Complementary portfolio in **gynaecology, dermatology**, and **wellness nutritionals**. - Strengthened **Naari (women’s health)** and **Unify (dermatology)** divisions. - Enhanced reach in **Maharashtra, Karnataka, and Kerala**. - Entry into **dermacosmeceuticals**, **acne**, **hair care**, and **moisturizers**. These acquisitions reflect **disciplined, bolt-on inorganic growth** with **no overlap**, **strong cultural fit**, and **strategic synergy**. --- #### **Product Portfolio & Brand Strength** - **Portfolio**: Over **75 products**, with a **concentrated focus**—**top 10 brands contribute 63%** of sales. - **Flagship Brands**: - **Indocap** (Indomethacin): First brand to cross **₹500 million sales**, maintains **#1 position** (84% market share). - **Indocap P** (FDC of Indomethacin + Paracetamol): Offers improved pain relief with **reduced side effects**. - **Lycored** series: #1 in female infertility; *Lycored M/Plus* offer enhanced antioxidant support. - **FeProtein**: First Indian comprehensive pregnancy care product for **anaemia management**. - **Divatrone** (Dydrogesterone): Launched in 2021, now a **growth anchor** in progesterone therapy. - **Product Lifecycle Management (PLCM)**: Rejuvenating legacy brands through **extensions, combinations, and repositioning**. --- #### **Distribution & Market Reach** - **Pan-India presence** in **over 4,000 towns and cities**. - Supported by: - **1,200+ distributors** - **18 strategically located stocking points** (up from 17) - Supply to **125,000+ pharmacies** nationwide - **Digital Enablement**: - **MySakhi**: A digital health platform for **women’s wellness**, offering expert content, myth-busting, and live consultations in **menstruation, fertility, and menopause**. --- #### **Financial & Operational Performance** - **FY2024–25 Performance Highlights**: - Revenue from key segments (IQVIA): - **Gynaecology**: ₹11,354 million (+3.8% YoY) - **Pain/Analgesics**: ₹186,250 million (+7.4%) - **Dermatology**: ₹16,397 million (+9.1%) - **Operating margin**: Exceeded **21%** post-transformation (up from ~11%). - **Working Capital Cycle**: Reduced from **60 to 13 days**, demonstrating **strong cash conversion**. - **Free Cash Flow**: Over **₹161 crores** generated in 3 years (FY22–FY25). - **Debt-Free Balance Sheet** with **surplus cash** for strategic deployment. - **Growth Targets**: - **>30% revenue growth in FY25**, **15%+ in FY26**, **12–14% long-term CAGR**. - **20%+ improvement in operating EBITDA** (FY26). - Long-term margin goal: **increase by 100–150 bps** beyond FY26. --- #### **Recent Challenges & Resilience** - **FY24 Headwinds**: - **Hypercompetition** in Dydrogesterone (Divatrone). - **Counterfeit versions** of *Indocap SR* impacted sales. - **Corrective Measures**: - Inventory corrections, enhanced **brand security features**, operational restructuring. - Strong **recovery in FY25** with positive growth across key brands. --- #### **Organizational Restructuring & Strategic Focus** - **Reorganized Business Divisions** (Sep 2025): - **FemBon**: Dedicated to **Gynaecology**. - **Boneva**: Focused on **Orthopaedics**. - **Naari**: Women's Health & Wellness. - **Unify**: Dermatology (integrated from Yash & Resilient). - Enables **targeted launches, deeper doctor engagement, and faster decision-making**.